ACM
TBPH icon

Aquatic Capital Management’s Theravance Biopharma TBPH Stock Holding History

Aquatic Capital Management’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-32,599
Closed -$529K – 1718
2026
Q1 		$529K Buy
+32,599
New +$577K 0.02% 741
2025
Q4 		– Sell
-16,768
Closed -$245K – 1762
2025
Q3 		$245K Sell
16,768
-19,476
-54% -$246K ﹤0.01% 1053
2025
Q2 		$400K Buy
36,244
+16,386
+83% +$159K 0.01% 877
2025
Q1 		$177K Buy
19,858
+17,254
+663% +$161K ﹤0.01% 963
2024
Q4 		$24.5K Buy
+2,604
New +$23.7K ﹤0.01% 1227
2024
Q3 		– Sell
-500
Closed -$4.24K – 1532
2024
Q2 		$4.24K Sell
500
-1,400
-74% -$12.6K ﹤0.01% 1148
2024
Q1 		$17K Buy
+1,900
New +$17.6K ﹤0.01% 1112
2023
Q4 		– Sell
-1,600
Closed -$14K – 1622
2023
Q3 		$14K Buy
+1,600
New +$15.4K ﹤0.01% 1105

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Aquatic Capital Management's TBPH Position: Q2 2026 in Review

Aquatic Capital Management sold out of Theravance Biopharma (TBPH) in Q2 2026, closing a stake of 32,599 shares — an estimated $529K sold.

Aquatic Capital Management first reported a position in TBPH in Q3 2023 and held it in 8 quarters. The position peaked at $529K in Q1 2026. 181 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

  • Aquatic Capital Management reported no remaining Theravance Biopharma position as of Q2 2026 after selling out during the quarter.
  • Aquatic Capital Management sold 32,599 Theravance Biopharma shares in Q2 2026, an estimated $529K.
  • Aquatic Capital Management first reported a position in Theravance Biopharma in Q3 2023 and held it in 8 quarters.
  • Aquatic Capital Management's Theravance Biopharma position peaked at $529K in Q1 2026.
  • 181 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on Aquatic Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.